The GMRF Clinical Trials Unit is currently recruiting for the following melanoma trials:
PROTOCOL: IOV-MEL-301 (TILVANCE-301) (PI: DR VICTORIA ATKINSON)
Protocol Title: A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma.
Lay Title: Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Click here for more information
PROTOCOL: IMCgp100-203 (PI: DR VICTORIA ATKINSON)
Protocol Title: Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Lay Title: Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Click here for more information
See Oncology General for other trials.